MGC Pharmaceuticals director shows support for company’s ArtemiC product with on-market purchase The company’s distributor Swiss PharmaCan recently increased its initial order volume for ArtemiC Rescue, an anti-inflammatory product targeting COVID-19, by 85%. Dr Parker previously did not hold any shares in the company. MGC Pharmaceuticals Ltd (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) director and Corporate Governance Committees chairman Dr Stephen B Parker has shown his support for the company's 'Nature to Medicine' strategy, including the ArtemiC product, with an on-market purchase. On March 5 Parker acquired 282,316 shares in an indirect interest for total consideration of £9,999.99 and this represented his first purchase.